UPCC 03423: A Phase 1b/2a Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
Brief description of study
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia.
We would like to rely on Advarra as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
12 Apr 2023.
Study ID: 853243
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
